{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:42:47Z","timestamp":1794008567237,"version":"4.8.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.annonc.2020.10.470","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T01:51:25Z","timestamp":1603072285000},"page":"103-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"title":["A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance"],"prefix":"10.1016","volume":"32","author":[{"given":"L.","family":"Tobalina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.","family":"Forment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.10.470_bib1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc.2016.72","article-title":"Hereditary breast and ovarian cancer: new genes in confined pathways","volume":"16","author":"Nielsen","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2020.10.470_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","article-title":"Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer","volume":"2","author":"Chen","year":"2018","journal-title":"Annu Rev Cancer Biol"},{"key":"10.1016\/j.annonc.2020.10.470_bib3","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2147\/OTT.S102569","article-title":"Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer","volume":"10","author":"Hollis","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.annonc.2020.10.470_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib6","first-page":"185","article-title":"The DNA damaging revolution: PARP inhibitors and beyond","volume":"39","author":"Yap","year":"2019","journal-title":"Dev Therap Tumor Biol"},{"key":"10.1016\/j.annonc.2020.10.470_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.10.470_bib8","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.10.470_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair"},{"key":"10.1016\/j.annonc.2020.10.470_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib12","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.10.470_bib13","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.10.470_bib14","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1158\/1078-0432.CCR-16-2174","article-title":"Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance","volume":"23","author":"Afghahi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.10.470_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clbc.2017.12.010","article-title":"BRCA2 reversion mutation associated with acquired resistance to olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy","volume":"18","author":"Gornstein","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.annonc.2020.10.470_bib16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2020.02.008","article-title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer","volume":"31","author":"Waks","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib17","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/2159-8290.CD-20-0163","article-title":"Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1\/2 and non-BRCA1\/2 mutant cancers","volume":"10","author":"Yap","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.10.470_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00268","article-title":"Direct ex\u00a0vivo observation of homologous recombination defect reversal after DNA-damaging chemotherapy in patients with metastatic breast cancer","volume":"3","author":"Meijer","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.annonc.2020.10.470_bib21","article-title":"Somatic reversion of germline BRCA2 mutation confers resistance to poly(ADP-ribose) polymerase inhibitor therapy","volume":"2","author":"Banda","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib22","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib23","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","article-title":"Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer","volume":"35","author":"Christie","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.10.470_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.10.470_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.gore.2017.06.010","article-title":"BRCA1 reversion mutation acquired after treatment identified by liquid biopsy","volume":"21","author":"Mayor","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.annonc.2020.10.470_bib28","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41416-018-0268-6","article-title":"Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer","volume":"119","author":"Patel","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.10.470_bib29","doi-asserted-by":"crossref","first-page":"e03841","DOI":"10.1016\/j.heliyon.2020.e03841","article-title":"The dynamic landscape of BRCA1 reversion mutations from INDEL to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy","volume":"6","author":"Jacob","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.annonc.2020.10.470_bib30","first-page":"3","article-title":"Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR","volume":"6","author":"Khalique","year":"2020","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.annonc.2020.10.470_bib31","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib32","first-page":"612","article-title":"Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation","volume":"12","author":"Tao","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.annonc.2020.10.470_bib33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2017.40","article-title":"BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer","volume":"116","author":"Pishvaian","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.10.470_bib34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","article-title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","volume":"7","author":"Quigley","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.10.470_bib35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.10.470_bib36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12885-020-6657-2","article-title":"Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report","volume":"20","author":"Simmons","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2020.10.470_bib37","first-page":"2","article-title":"Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in BRCA2-associated prostate cancer resulting from biallelic BRCA2 reversion mutations restores both germline and somatic loss-of-function mutations","volume":"2","author":"Carneiro","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib38","article-title":"Polyclonal BRCA2 reversion mutations detected in circulating tumor DNA after platinum chemotherapy in a patient with metastatic prostate cancer","volume":"2","author":"Cheng","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2020.10.470_bib39","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1158\/1078-0432.CCR-19-2933","article-title":"Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors","volume":"26","author":"Vidula","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.10.470_bib40","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1093\/nar\/gky653","article-title":"Decoding non-random mutational signatures at Cas9 targeted sites","volume":"46","author":"Taheri-Ghahfarokhi","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.annonc.2020.10.470_bib41","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/bioinformatics\/bti525","article-title":"BioMart and bioconductor: a powerful link between biological databases and microarray data analysis","volume":"21","author":"Durinck","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.annonc.2020.10.470_bib42","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/nprot.2009.97","article-title":"Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt","volume":"4","author":"Durinck","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.annonc.2020.10.470_bib43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/humu.20654","article-title":"Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker","volume":"29","author":"Wildeman","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.annonc.2020.10.470_bib44","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2020.10.470_bib45","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.10.470_bib46","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.10.470_bib47","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.10.470_bib48","first-page":"1059","article-title":"Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families","volume":"60","author":"Levy-Lahad","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.annonc.2020.10.470_bib49","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","article-title":"The BRCA1-delta11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.10.470_bib50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nsmb.3236","article-title":"Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection","volume":"23","author":"Densham","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.annonc.2020.10.470_bib51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","article-title":"Accurate classification of BRCA1 variants with saturation genome editing","volume":"562","author":"Findlay","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib52","doi-asserted-by":"crossref","first-page":"e21350","DOI":"10.7554\/eLife.21350","article-title":"Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance","volume":"6","author":"Anantha","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.annonc.2020.10.470_bib53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature01230","article-title":"Insights into DNA recombination from the structure of a RAD51-BRCA2 complex","volume":"420","author":"Pellegrini","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib54","doi-asserted-by":"crossref","first-page":"e1002409","DOI":"10.1371\/journal.pgen.1002409","article-title":"Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains","volume":"7","author":"Siaud","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.annonc.2020.10.470_bib55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ng747","article-title":"Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer","volume":"29","author":"Jonkers","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.10.470_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.annonc.2020.10.470_bib57","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib58","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1038\/s41467-019-13530-6","article-title":"BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2020.10.470_bib59","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.10.470_bib60","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2020.10.470_bib61","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI70196","article-title":"BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1","volume":"126","author":"Drost","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.annonc.2020.10.470_bib62","doi-asserted-by":"crossref","first-page":"e9172","DOI":"10.15252\/emmm.201809172","article-title":"A\u00a0RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.annonc.2020.10.470_bib63","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1209909","article-title":"BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity","volume":"334","author":"Shakya","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.annonc.2020.10.470_bib64","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","article-title":"BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance","volume":"20","author":"Drost","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2020.10.470_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10371","article-title":"BRCA1 tumour suppression occurs via heterochromatin-mediated silencing","volume":"477","author":"Zhu","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib66","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2020.10.470_bib67","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1363-4","article-title":"Isomerization of BRCA1\u2013BARD1 promotes replication fork protection","volume":"571","author":"Daza-Martin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.10.470_bib68","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2018.03.005","article-title":"Targeting the replication stress response in cancer","volume":"188","author":"Forment","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.annonc.2020.10.470_bib69","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.molcel.2018.08.020","article-title":"Comprehensive mapping of histone modifications at DNA double-strand breaks deciphers repair pathway chromatin signatures","volume":"72","author":"Clouaire","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.annonc.2020.10.470_bib70","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/cmdc.201700143","article-title":"Targeting DNA-dependent protein kinase for cancer therapy","volume":"12","author":"Harnor","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.annonc.2020.10.470_bib71","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2020.10.470_bib72","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.molcel.2016.06.020","article-title":"Essential roles for polymerase theta-mediated end joining in the repair of chromosome breaks","volume":"63","author":"Wyatt","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.annonc.2020.10.470_bib73","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature14157","article-title":"Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination","volume":"518","author":"Mateos-Gomez","year":"2015","journal-title":"Nature"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342042962X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342042962X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:00:39Z","timestamp":1760335239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342042962X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S092375342042962X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.10.470","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.22.215673","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.10.470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}